The company, founded by 25-year-old Kian Sadeghi, announced a $14 million Series A, bringing its total funding to about $32 million.
A patient found to carry a BRCA1 pathogenic variant is not referred to a certified genetic counselor in her health system.
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback